Recogen

Recogen is a China-based biotechnology company focused on mRNA vaccines, particularly infectious disease vaccines. It was established in 2021 in Wuhan as a joint venture associated with Jiangsu Recbio Technology and Shenzhen Rhegen Biotechnology, and has been described by Recbio as a subsidiary specializing in mRNA infectious vaccines. The company developed lyophilized mRNA-LNP COVID-19 vaccine candidates designed for storage under conventional cold-chain conditions rather than ultra-cold logistics. Its disclosed lead programs include RH109 and R520A, both directed at SARS-CoV-2, including Omicron-focused development. Available third-party sources indicate the company was later listed as dissolved, and its known clinical studies were early-stage Phase 1 trials that were withdrawn for business strategy reasons.